Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Moseley, B. E.B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moseley, B. E.B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Safety Assessment and Public Concern for Genetically Modified Food Products: The European View

Bevan E.B. Moseley

Blandford House, Reading, Berkshire RG1 5RD, United Kingdom, bevmos{at}bmoseley.fsnet.co.uk

The safety assessment for marketing purposes of genetically modified (GM) foods in the 15 Member States of the European Union (EU) is based on the Novel Foods and Novel Food Ingredients Regulation adopted in May 1997. Before a GM food can be approved under the Regulation, it must satisfy three criteria: Gm food must be safe, it must not mislead the consumer and it must be nutritionally adequate. The EU Scientific Committee on Food has published a set of guidelines describing the type of information expected from a company in support of an application for approval of a GM food or food ingredient. Despite this rigorous procedure and there being no evidence of harm resulting from the consumption of GM foods worldwide, there is essentially no market in the EU for such products at present. Possible reasons for this are discussed and the view put forward that the market for GM foods will change only when there are more clearly perceived consumer benefits.

Key Words: Food safety • safety regulations • substantial equivalence • genetically modified food • public concerns • regulation • European Union.

References

  • Anonymous (1997a). Commission recommendation 97/618/EC concerning the scientific aspects and the presentation of information necessary to support applications for the placing on the market of novel foods and novel food ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the Council. Official J Eur Communities L 253/1-36, 16 September 1997.
  • Anonymous (1997b). Regulation (EC) No 258/97 oftheEuropeanParliament and of the Council of 25 January 1997 concerning novel foods and novel food ingredients. Official J Eur Communities L 43:
  • Chesson A. (2001). Assessing the safety of GM food crops. In: Food Safety and Food Quality, Issues in Environmental Science and Technology No 15, Hester RE, Harrison RM (eds). The Royal Society of Chemistry, Cambridge UK, pp 1—24.
  • Frewer LJ, Shepherd R. (1998). Consumer perceptions of modern food biotechnology. In: Genetic Modification in the Food Industry, Roller S, Harlander S (eds). Blackie, London, UK, pp 27—46.
  • Millstone E., Brunner E., Mayer S. (1999). Beyond `substantial equivalence '. Nature 401: 525—526.[CrossRef][Medline] [Order article via Infotrieve]
  • Oecd (1993). Safety Evaluation of Foods Produced by Modern Biotechnology— Concepts and Principles, OECD, Paris.
  • Reiss MJ, Straughan R. (1966). Improving Nature? The Science and Ethics of Genetic Engineering. Cambridge University Press, Cambridge UK.
  • Straughan R. (1998). Moral concerns and the educational function of ethics. In: Genetic Modification in the Food Industry, Roller S, Harlander S (eds). Blackie, London, UK, pp 47—60.

Toxicologic Pathology, Vol. 30, No. 1, 129-131 (2002)
DOI: 10.1080/01926230252824824


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Moseley, B. E.B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moseley, B. E.B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?